Tiverton Asset Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Tiverton Asset Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-17,364	Closed	-$40K	–	674
2018 Q4	$40K	Sell	17,364 -67,389	-80%	-$594K	﹤0.01%	469
2018 Q3	$1.26M	Buy	84,753 +6,722	+9%	+$107K	0.06%	179
2018 Q2	$1.19M	Buy	78,031 +23,031	+42%	+$391K	0.06%	168
2018 Q1	$1.03M	Buy	+55,000	New	+$961K	0.07%	149

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tiverton Asset Management's SNNA Position: Q1 2019 in Review

Tiverton Asset Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 17,364 shares — an estimated $40K sold.

Tiverton Asset Management first reported a position in SNNA in Q1 2018 and held it in 4 quarters. The position peaked at $1.26M in Q3 2018. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

Tiverton Asset Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Tiverton Asset Management sold 17,364 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $40K.
Tiverton Asset Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Tiverton Asset Management's Sienna Biopharmaceuticals, Inc. position peaked at $1.26M in Q3 2018.
57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on Tiverton Asset Management's 13F filing for Q1 2019, filed 13 May 2019.